Relmada Therapeutics (RLMD) EBIT (2012 - 2026)

Relmada Therapeutics (RLMD) has reported EBIT for 15 consecutive years, with -$19.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBIT fell 6.82% year-over-year to -$19.5 million; the TTM figure through Mar 2026 stood at -$60.3 million (up 23.73% YoY), while the FY2025 annual figure was -$59.1 million, up 29.55% from the prior year.
• EBIT climbed to -$19.5 million in Q1 2026 per RLMD's latest filing, from -$20.3 million in the prior quarter.
• Across five years, EBIT topped out at -$10.2 million in Q2 2025 and bottomed at -$45.5 million in Q2 2022.
• Historically, EBIT has averaged -$25.1 million across 5 years, with a median of -$23.0 million in 2024.
• Annual changes were most pronounced in 2022 — EBIT sank 71.99% — and 2025, when it surged 55.12%.
• Relmada Therapeutics' EBIT stood at -$38.7 million in 2022, then soared by 30.68% to -$26.8 million in 2023, then climbed by 28.9% to -$19.1 million in 2024, then declined by 6.59% to -$20.3 million in 2025, then grew by 4.29% to -$19.5 million in 2026.
• Business Quant data shows RLMD's EBIT at -$19.5 million in Q1 2026, -$20.3 million in Q4 2025, and -$10.3 million in Q3 2025.